title: Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
abstract: Soluble receptors for several cytokines have been detected in body fluids and are believed to modulate the cytokine response by binding the ligand and thereby reducing its bioavailability. In the case of IL-6, the situation is more complex. The receptor consists of two components, including a ligand-binding alpha-subunit (IL-6R, gp80, or CD126), which in its soluble (s) form (sIL-6R) acts agonistically by making the ligand accessible to the second subunit, the signal transducer gp130 (CD130). Soluble forms of both receptor subunits are present in human blood. Gel filtration of iodinated IL-6 that had been incubated with human serum revealed that IL-6 is partially trapped in IL-6/sIL-6R/sgp130 ternary complexes. sgp130 from human plasma was enriched by immunoaffinity chromatography and identified as a 100-kDa protein. Functionally equivalent rsgp130 was produced in baculovirus-infected insect cells to study its antagonistic potential on four different cell types. It was found that in situations in which cells lacking membrane-bound IL-6R were stimulated with IL-6/sIL-6R complexes, sgp130 was a much more potent antagonist than it was on IL-6R-positive cells stimulated with IL-6 alone. In the latter case, the neutralizing activity of sgp130 could be markedly enhanced by addition of sIL-6R. As a consequence of these findings, sIL-6R of human plasma must be regarded as an antagonistic molecule that enhances the inhibitory activity of sgp130. Furthermore, in combination with sIL-6R, sgp130 is a promising candidate for the development of IL-6 antagonists.
authors.affiliation: Institut für Biochemie, Rheinisch-Westfälische Technische Hochschule Aachen, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Müller-Newen
authors.forename: A
authors.initials: A
authors.lastname: Küster
authors.forename: U
authors.initials: U
authors.lastname: Hemmann
authors.forename: R
authors.initials: R
authors.lastname: Keul
authors.forename: U
authors.initials: U
authors.lastname: Horsten
authors.forename: A
authors.initials: A
authors.lastname: Martens
authors.forename: L
authors.initials: L
authors.lastname: Graeve
authors.forename: J
authors.initials: J
authors.lastname: Wijdenes
authors.forename: P C
authors.initials: PC
authors.lastname: Heinrich
mesh_terms: D000276:Adjuvants, Immunologic / Q000502:physiology*; D000818:Animals; D015703:Antigens, CD / Q000097:blood / Q000737:chemistry / Q000235:genetics / Q000502:physiology*; D016367:Baculoviridae / Q000235:genetics; D019556:COS Cells; D002460:Cell Line; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D050822:Cytokine Receptor gp130; D004285:Dogs; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005822:Genetic Vectors / Q000378:metabolism; D006801:Humans; D015850:Interleukin-6 / Q000097:blood / Q000502:physiology; D007668:Kidney / Q000166:cytology; D046911:Macromolecular Substances; D008562:Membrane Glycoproteins / Q000097:blood / Q000737:chemistry / Q000235:genetics / Q000502:physiology*; D019947:Receptors, Interleukin-6 / Q000819:agonists / Q000097:blood / Q000502:physiology*; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000737:chemistry; D015398:Signal Transduction / Q000276:immunology; D012995:Solubility; D018411:Spodoptera / Q000235:genetics; D000093242:Interleukin-6 Inhibitors
chemical_list: D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D050822:Cytokine Receptor gp130; D015850:Interleukin-6; D046911:Macromolecular Substances; D008562:Membrane Glycoproteins; D019947:Receptors, Interleukin-6; D011994:Recombinant Proteins; D000093242:Interleukin-6 Inhibitors; C494199:IL6ST protein, human